Connect your AI

Beam Therapeutics BEAM Payments Of Debt Issuance Costs

Payments Of Debt Issuance Costs at other companies

Arrowhead ResearchARWR

——

CRISPR TherapeuticsCRSP

——

Dyne Therapeutics, Inc.DYN

——

BioMarin PharmaceuticalsBMRN

——

Other financials

Income statement

Revenue$31.7M+325%

Operating income-$107.2M+10.1%

Net income-$94.3M+12.9%

EPS (diluted)-$0.91+26.0%

Balance sheet

Cash & equivalents$288.3M-45.4%

Total debt$250.8M+58.6%

Total equity$1.2B+3.1%

Total assets$1.5B+0.9%

Cash flow

Operating cash flow-$128.5M-23.7%

CapEx$2.2M-27.2%

Free cash flow-$130.7M-22.2%

Valuation

Market cap$3.42B+24.5%

Profitability

Operating margin-226.6%-90.5pp

Net margin-742.7%—

FCF margin-234%-86.6pp

Returns & leverage

Return on equity-47.1%—

Debt / equity0.2×+0.1×

Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's payments of debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Beam Therapeutics's payments of debt issuance costs?: Beam Therapeutics (BEAM) reported payments of debt issuance costs of $813K in Q1 2026.